A phase I investigator initiated inhalation safety trial of AB569 in healthy volunteers.

Trial Profile

A phase I investigator initiated inhalation safety trial of AB569 in healthy volunteers.

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Nitrite (Primary)
  • Indications Burkholderia cepacia infections; Pseudomonal infections; Staphylococcal infections
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Apr 2017 Dr. Ralph Panos is the lead investigator of this trial, according to an Arch Biopartners media release.
    • 27 Feb 2017 New trial record
    • 27 Oct 2016 According to Arch Biopartners media release, the application for this trial is expected to be submitted to the internal review board (IRB) of the CVAMC by December, 2016. IRB feedback is anticipated before January, 2017 and the trial is expected to start immediately upon an approval to proceed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top